Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Clin Chim Acta. 2018 Jul;482:101-107. doi: 10.1016/j.cca.2018.03.038. Epub 2018 Mar 31.
Programmed cell death-ligand 1 (PD-L1) seemed to be associated with the outcomes of non-small cell lung cancer. However the prognostic role of PD-L1 expression among NSCLC remained unclear and inconsistent. The aim of the study set out to evaluate the correlation between PD-L1 expression and the prognosis of patients that developed NSCLC.
Identified literatures were extracted of various electronic databases and a meta-analysis was performed to evaluate the prognostic role of PD-L1 among NSCLC patients.
Totally 25 studies from 11 countries containing 5861 patients were included in the meta-analysis. The pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were 1.176 (95% CI: 1.016-1.361, P = 0.029) and 1.170 (95% CI: 0.984-1.392, P = 0.076), respectively. High PD-L1 expression on NSCLC tissue was also related with worse OS among Asian patients (HR = 1.381, 95% CI: 1.127-1.629, P = 0.002), adenocarcinomas (HR = 1.899, 95% CI: 1.306-2.762, P = 0.001) and poor PFS in non-Asian patients (HR = 1.695, 95% CI: 1.158-2.480, P = 0.002). Sensitivity analysis indicated that removal of any particular included literature won't affect the pooled results. Publication bias among the studies was not significant neither.
PD-L1 expression is a prognostic factor related with poor survival among patients that developed NSCLC.
程序性死亡配体 1(PD-L1)似乎与非小细胞肺癌(NSCLC)的预后相关。然而,PD-L1 表达在 NSCLC 中的预后作用尚不清楚且不一致。本研究旨在评估 PD-L1 表达与 NSCLC 患者预后的相关性。
从多个电子数据库中提取了已识别的文献,并进行了荟萃分析,以评估 PD-L1 在 NSCLC 患者中的预后作用。
共有来自 11 个国家的 25 项研究,包含 5861 名患者,被纳入荟萃分析。总生存(OS)和无进展生存(PFS)的合并风险比(HR)分别为 1.176(95%CI:1.016-1.361,P=0.029)和 1.170(95%CI:0.984-1.392,P=0.076)。NSCLC 组织中高 PD-L1 表达也与亚洲患者的 OS 更差相关(HR=1.381,95%CI:1.127-1.629,P=0.002)、腺癌(HR=1.899,95%CI:1.306-2.762,P=0.001)和非亚洲患者的 PFS 更差(HR=1.695,95%CI:1.158-2.480,P=0.002)。敏感性分析表明,去除任何特定的纳入文献都不会影响合并结果。研究之间也没有明显的发表偏倚。
PD-L1 表达是与 NSCLC 患者不良生存相关的预后因素。